Orphan drug approvals of 2014: Europe and the United States

Bibliography

• FDA. Novel New Drugs 2014 Summary. 2015. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf
   Google Scholar
• PNorman. Orphan Drug Approvals in Europe since 2001; an analysis by indication. Expert Opin Orphan Drugs 2013;1(2):131-9
   Web of Science ®Google Scholar
• WFox, GAEllard, DAMitchison. Studies on the treatment of tuberculosis undertaken by the british medical research council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-79
   PubMed Web of Science ®Google Scholar
• ELeibert, MDanckers, WNRom. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014;10:597-602
   PubMed Web of Science ®Google Scholar
• HABlair, LJScott. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015;75(1):91-100
   PubMedGoogle Scholar
• HNoh, JILee. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 2014;39(3):215-24
   PubMed Web of Science ®Google Scholar
• KALyseng-Williamson. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). BioDrugs 2014;28(5):465-75
   PubMed Web of Science ®Google Scholar
• EMWelch, ERBarton, JZhuo, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447(7140):87-91
   PubMed Web of Science ®Google Scholar
• MHaas, VVlcek, PBalabanov, et al. European medicines agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 2015;25(1):5-13
   PubMed Web of Science ®Google Scholar
• MEHorner, AAlikhan, STintle, et al. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol 2013;52(12):1464-80
   PubMedGoogle Scholar
• EIMinder, XSchneider-Yin. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol 2015;8(1):43-53
   PubMed Web of Science ®Google Scholar
• GBiolcati, EMarchesini, FSorge, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 2014. [Epub ahead of print]
   Google Scholar
• DKhaybullina, APatel, TZerilli. Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T 2014;39(11):749-58
   PubMedGoogle Scholar
• JRColombo, ROWein. Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag 2014;10:395-404
   PubMed Web of Science ®Google Scholar
• YCLiu, KStone, Fvan Rhee. Siltuximab for multicentric Castleman disease. Expert Rev Hematol 2014;7(5):545-57
   PubMed Web of Science ®Google Scholar
• CKlein, ALammens, WSchäfer, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2013;5(1):22-33
   PubMed Web of Science ®Google Scholar
• KARogers, JAJones. Obinutuzumab for the treatment of chronic lymphocytic leukemia. Drugs Today (Barc) 2014;50(6):407-19
   PubMed Web of Science ®Google Scholar
• AAalipour, RHAdvani. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol 2014;5(4):121-33
   PubMedGoogle Scholar
• PLoli, MEBerselli, MTagliaferri. Use of ketoconazole in the treatment of Cushing’s syndrome. J Clin Endocrinol Metab 1986;63(6):1365-71
   PubMed Web of Science ®Google Scholar
• DCuevas-Ramos, MFleseriu. Treatment of Cushing’s disease: a mechanistic update. J Endocrinol 2014;223(2):R19-39
   PubMed Web of Science ®Google Scholar
• CMarchetti, LImperiale, MLGasparri, et al. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 2012;21(10):1575-84
   PubMed Web of Science ®Google Scholar
• AMOza, DCibula, AOBenzaquen, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncol 2015;16(1):87-97
   PubMed Web of Science ®Google Scholar
• IMarech, RPatruno, NZizzo, et al. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 2014;91(1):98-111
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Record number of medicines for rare diseases recommended for approval in 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002247.jsp&mid=WC0b01ac058004d5c1 [Last accessed 9 January 2015]
   Google Scholar
• AGuarnieri, JMoreno-Montañés, BAlfonso-Bartolozzi, et al. Quantification of corneal neovascularization after ex vivo limbal epithelial stem cell therapy. Int J Ophthalmol 2014;7(6):988-95
   PubMed Web of Science ®Google Scholar
• LLandi, FCappuzzo. Ceritinib for the treatment of non-small cell lung cancer. Drugs Today (Barc) 2014;50(7):465-73
   PubMedGoogle Scholar
• MKhan, ASaif, SSandler, et al. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol 2014;2014:931858
   PubMedGoogle Scholar
• JPLopez, AJimeno. Idelalisib for the treatment of indolent non-Hodgkin’s lymphoma. Drugs Today (Barc) 2014;50(2):113-20
   PubMedGoogle Scholar
• MEBjørn, Kde Stricker, LKjær, et al. Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep 2014;3(2):73-5
   PubMedGoogle Scholar
• SNovello, RKaiser, AMellemgaard, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer 2015;51(3):317-26
   PubMed Web of Science ®Google Scholar
• NAwasthi, SHinz, RABrekken, et al. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett 2015;358(1):59-66
   PubMedGoogle Scholar
• LRicheldi, RMdu Bois, GRaghu, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071-82
   PubMed Web of Science ®Google Scholar
• JMcDermott, AJimeno. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc) 2014;50(5):337-45
   PubMedGoogle Scholar
• ABodiford, MBodge, MSTalbott, et al. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets Ther 2014;7:1971-7
   PubMed Web of Science ®Google Scholar
• KTFlaherty, JRInfante, ADaud, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• PMomtaz, MAPostow. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65
   PubMedGoogle Scholar
• EMaverakis, LACornelius, GMBowen, et al. Metastatic Melanoma-A review of current and future treatment options. Acta Derm Venereol 2014. [Epub ahead of print]
   Google Scholar
• CRobert, ARibas, JDWolchok, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase I trial. Lancet 2014;384(9948):1109-17
   PubMed Web of Science ®Google Scholar
• CRobert, GVLong, BBrady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30
   PubMed Web of Science ®Google Scholar
• KShitara, AOhtsu. Ramucirumab for gastric cancer. Expert Rev Gastroenterol Hepatol 2015;9(2):133-9
   PubMed Web of Science ®Google Scholar
• GO’Sullivan Coyne, MBurotto. Clinical experience with ramucirumab : outcomes in breast cancer. Expert Opin Biol Ther 2014;14(9):1351-60
   PubMed Web of Science ®Google Scholar
• MSTopp, NGökbuget, GZugmaier, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32(36):4134-40
   PubMed Web of Science ®Google Scholar
• XThomas. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol 2015;16(1):6-7
   PubMed Web of Science ®Google Scholar
• PKawalec, PHolko, APaszulewicz. Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema. Postepy Dermatol Alergol 2013;30(3):152-8
   PubMedGoogle Scholar
• NAOrlova, SVKovnir, IIVorobiev, et al. Coagulation factor IX for hemophilia B therapy. Acta Naturae 2012;4(2):62-73
   PubMed Web of Science ®Google Scholar
• JMDucore, MGMiguelino, JSPowell. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol 2014;7(5):559-71
   PubMed Web of Science ®Google Scholar
• ADShapiro, MVRagni, RKulkarni, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014;12(11):1788-800
   PubMed Web of Science ®Google Scholar
• JNLozier, KNghiem, MLee, et al. Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone. Haemophilia 2014;20(2):e185-8
   PubMedGoogle Scholar
• MKreuter. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev 2014;23(131):111-17
   PubMedGoogle Scholar
• TEKingJr, WZBradford, SCastro-Bernardini, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083-92
   PubMed Web of Science ®Google Scholar
• JAShayman. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs Future 2010;35(8):613-20
   PubMed Web of Science ®Google Scholar
• SMStahl. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectr 2014;19(6):475-8
   PubMed Web of Science ®Google Scholar
• CLavedan, MForsberg, AJGentile. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology 2015;91:142-7
   PubMed Web of Science ®Google Scholar
• DALankford. Tasimelteon for insomnia. Expert Opin Investig Drugs 2011;20(7):987-93
   PubMed Web of Science ®Google Scholar
• GGHarrison. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975;47(1):62-5
   PubMedGoogle Scholar
• JLChan, KLutz, ECochran, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract 2011;17(6):922-32
   PubMed Web of Science ®Google Scholar
• JLBaker, MPu, CATokin, et al. Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients. Ann Surg Oncol 2015;22(1):40-5
   PubMedGoogle Scholar
• DSGoldstein. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 2006;24(3-4):189-203
   PubMedGoogle Scholar
• SHIsaacson, JSkettini. Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag 2014;10:169-76
   PubMedGoogle Scholar
• HEibl, CUnger. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 1990;17(2-3):233-42
   PubMedGoogle Scholar
• HWMurray. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000;4(3):158-77
   PubMedGoogle Scholar
• TPDorlo, MBalasegaram, JHBeijnen, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012;67(11):2576-97
   PubMed Web of Science ®Google Scholar
• MOksiuta, EMatuszczak, WDebek, et al. Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. J Matern Fetal Neonatal Med 2014;1-5
   Google Scholar
• KSchmiegelow, SNNielsen, TLFrandsen, et al. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 2014;36(7):503-17
   PubMed Web of Science ®Google Scholar
• LWillis, ARexwinkle, JBryan, TMKadia. Recent developments in drug therapy for aplastic anemia. Ann Pharmacother 2014;48(11):1469-78
   PubMedGoogle Scholar
• JMWillatt, IRFrancis, PMNovelli, et al. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88
   PubMedGoogle Scholar